Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension
This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular...
Brief Summary
This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
- Study Primary Completion Date: August 2006
Intervention(s) in this Clinical Trial
- Drug: brimonidine
Outcome Measures for this Clinical Trial
Primary Measures
- lowering of intraocular pressure
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- ocular hypertension or glaucoma in both eyes
- currently treated with brimonidine
- requires IOP-lowering therapy in both eyes
Exclusion Criteria:
- uncontrolled systemic disease
- known allergy or sensitivity to brimonidine
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Allergan Industry
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00168363
Study ID Number: 190342-022
ClinicalTrials.gov Identifier: NCT00168363
Health Authority: United States: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00168363
